Tracey Roizman

Black patients have significantly longer median time to appropriate antibiotic treatment than Whites Black patients are more likely to be diagnosed with disseminated manifestations of Lyme disease (LD) and experience longer time to appropriate treatment, according to a research letter published online Dec. 12 in JAMA Network Open. Samuel J. Starke, M.D., from the Johns Hopkins...

PLCOm2012 models have higher sensitivity than USPSTF criteria, with no difference by Indigenous classification Two versions of the PLCOm2012 risk‐prediction model (based on the 2012 Prostate, Lung, Colorectal, and Ovarian [PLCO] Cancer Screening Trial), with and without a predictor for race, have high sensitivities for lung cancer, according to a study published online Oct. 9...

Secukinumab, a fully human monoclonal antibody that targets IL-17A, is a promising treatment option in pediatric patients aged 6 years and above with moderate to severe plaque psoriasis. Psoriasis is a chronic and inflammatory skin disease that affects 1% to 5% of the global population. It is caused by T-cell activity and genetic and epigenetic...

Phototherapy is a promising treatment option for various skin conditions, but further research is needed to explore its full potential and safety. Non-invasive phototherapy using LED technology is becoming popular for medical and aesthetic dermatological conditions. Studies have shown that these treatments can promote wound healing and reduce inflammation. Recent studies using blue light have...

The combination of venetoclax and selinexor alongside chemotherapy was well-tolerated in patients with relapsed or refractory acute myeloid leukemia in a recent data analysis of a phase 1 study. Children and adolescents/young adults with relapsed or refractory acute myeloid leukemia (R/R AML) continue to have poor survival rates. In children with R/R AML, prior clinical...

Selinexor in combination with venetoclax and azacitidine (the SAV regimen) is safe and effective, with encouraging complete response rates, according to a recent prospective study. Acute myeloid leukemia (AML) primarily affects older people, who are frequently unable to endure intense chemotherapy due to frailty or comorbid conditions. While venetoclax with azacytidine has a 64% response...

 Variations in the degree of venous malformation tissue involvement and thrombin–antithrombin complex/D-dimer correlation could point to a coagulopathy progressing proportionally to the degree of VM, according to a retrospective study. Although poorly understood, localized intravascular coagulopathy (LIC) is a known consequence of venous malformations (VMs) that can cause thrombosis, bleeding, and the development of phleboliths....

After years of hydroxyurea treatment for pediatric patients with sickle cell disease, nearly 30% of children experienced a significant decrease in fetal hemoglobin levels, resulting in an increase in clinical complictions. By stimulating the expression of fetal hemoglobin (HbF), hydroxyurea helps patients with sickle cell disease (SCD). Improved clinical outcomes are correlated with higher HbF...

GBT021601, a potent sickle hemoglobin polymerization inhibitor, reduces abnormal angiogenesis and ineffective erythropoiesis, which may help sickle cell disease patients benefit from cell-based therapy, according to the results of a preliminary study. Damage from hypoxia results in abnormal blood vessel formation in sickle cell disease (SCD), which affects bone marrow and red blood cell production....